• Introduction
  • All Faculty
  • Full Time & Joint Faculty
  • Professors Emeritus
  • Associate Faculty
  • Part Time Faculty
• Gallery of Distinguished Faculty
• Accolades & Awards
• Connect to Research Expertise
• Faculty Reflections

Clinical Epidemiology & Biostatistics

Hertzel C. Gerstein

Academic Interests

Dr. Hertzel C. Gerstein's academic interests include: a) using population health approaches to reduce the burden of diabetes in society and to prevent new diabetes; b) measuring the burden of diabetes in Canada; c) using epidemiologic approaches to study the relationship between dysglycemia, diabetes and cardiovascular disease; andd) clinical trials in the prevention & therapy of dysglycemia, diabetes and their consequences.
His research is funded by the US National Institutes of Health, the Canadian Institutes of Health Research, Heart & Stroke Foundation, and the Canadian Diabetes Association. Some of his current roles include  principal investigator (PI) of the ORIGIN trial, REWIND trial, and ACCORDION follow-up study of cardiovascular prevention in type 2 diabetes; chair of the REMIT trial assessing therapies to promote type 2 diabetes remission, coPI of the EpiDREAM study of dysglycemic & normoglycemic individuals.  

Current Graduate Students

Gaya Amirthavasar
Deepa Yoganathan
Gina Agarwal
Natalia Yakubovich

Selected Publications

1. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Card Prev Rehab (Epub May 6, 2011)
2. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Garrido M, MacKinnon I, Rao PV, Zinman B, Jung H, Joldersma L, Bosch J, Yusuf S. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2011;(3):487-95.
3. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med; 2011:364(9):818-28.
4. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011;123(3):342-8. PMID: 21263007
5. Boyko EJ, Gerstein HC, Mohan V, Yusuf S, Sheridan P, Anand S, Shaw JE, DREAM trial investigators. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetic Medicine 2010: 2010;27(11):1226-32.
6. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-44.
7. Gerstein HC, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, Lang CC, Luna MA, McQueen M, Rangarajan S, Rosengren A, Wang X, Yusuf S. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia. 2010: 53(12):2509-17.
8. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010; 376(9735):103-111.
9. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-74. (PMID 20228401)
10. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17):1563-74. (PMID 20228404)

Search for citations for Dr. Gerstein on PubMed